{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:36:53Z","timestamp":1791308213843,"version":"4.3.1"},"reference-count":34,"publisher":"American Association for Cancer Research (AACR)","issue":"23","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Purpose: Amatuximab is a chimeric monoclonal antibody to mesothelin, a cell surface glycoprotein highly expressed in malignant pleural mesothelioma (MPM). On the basis of its synergy with chemotherapy in preclinical studies, we evaluated the antitumor activity of amatuximab plus pemetrexed and cisplatin in patients with unresectable MPM.<\/jats:p>\n                  <jats:p>Experimental Design: In a single-arm phase II study, amatuximab (5 mg\/kg) was administered on days 1 and 8 with pemetrexed (500 mg\/m2) and cisplatin (75 mg\/m2) on day 1 of 21-day cycles for up to six cycles. Patients with response or stable disease received amatuximab maintenance until disease progression. Primary endpoint was progression-free survival (PFS) at 6 months. Secondary endpoints were overall survival (OS), response rate, and safety.<\/jats:p>\n                  <jats:p>Results: Eighty-nine patients were enrolled at 26 centers. Median of five cycles (range, 1\u20136) of combination treatment was administered, and 56 (63%) patients received amatuximab maintenance. Combination therapy resulted in no overlapping toxicities. Eleven patients (12.4%) had amatuximab-related hypersensitivity reactions. Responses included partial responses in 33 (40%) and stable disease in 42 (51%). Six-month PFS rate was 51% [95% confidence interval (CI), 39.1\u201362.3)], median PFS was 6.1 months (95% CI, 5.8\u20136.4), and median OS was 14.8 months (95% CI, 12.4\u201318.5) with 29 patients alive at data cut-off.<\/jats:p>\n                  <jats:p>Conclusions: Amatuximab with pemetrexed and cisplatin was well tolerated with objective tumor response or stable disease rate of 90% by independent radiologic review. Although PFS was not significantly different from historical controls, the median OS was 14.8 months with a third of patients alive and 5 continuing to receive amatuximab at the time of analysis. Clin Cancer Res; 20(23); 5927\u201336. \u00a92014 AACR.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-14-0804","type":"journal-article","created":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T02:57:46Z","timestamp":1411009066000},"page":"5927-5936","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":156,"title":["Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma"],"prefix":"10.1158","volume":"20","author":[{"given":"Raffit","family":"Hassan","sequence":"first","affiliation":[{"name":"1Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedy L.","family":"Kindler","sequence":"additional","affiliation":[{"name":"2University of Chicago, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Jahan","sequence":"additional","affiliation":[{"name":"3University of California, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyudmila","family":"Bazhenova","sequence":"additional","affiliation":[{"name":"4University of California, San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[{"name":"5Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Member of the German Center for Lung Research (DZL), Grosshansdorf, Stormarn, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Thomas","sequence":"additional","affiliation":[{"name":"1Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[{"name":"6Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Parno","sequence":"additional","affiliation":[{"name":"7United BioSource Corp., Blue Bell, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"O'Shannessy","sequence":"additional","affiliation":[{"name":"8Morphotek, Inc., Exton, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"Fatato","sequence":"additional","affiliation":[{"name":"8Morphotek, Inc., Exton, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia D.","family":"Maltzman","sequence":"additional","affiliation":[{"name":"8Morphotek, Inc., Exton, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Wallin","sequence":"additional","affiliation":[{"name":"8Morphotek, Inc., Exton, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2014,11,30]]},"reference":[{"key":"2022061021010994300_bib1","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/00000658-199609000-00005","article-title":"Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma - Results in 120 consecutive patients.","volume":"224","author":"Sugarbaker","year":"1996","journal-title":"Ann Surg"},{"key":"2022061021010994300_bib2","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"2022061021010994300_bib3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/1097-0142(19930715)72:2<410::AID-CNCR2820720216>3.0.CO;2-G","article-title":"Prognostic factors of malignant mesothelioma of the pleura.","volume":"72","author":"Manzini","year":"1993","journal-title":"Cancer"},{"key":"2022061021010994300_bib4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.2910500308","article-title":"Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium.","volume":"50","author":"Chang","year":"1992","journal-title":"Int J Cancer"},{"key":"2022061021010994300_bib5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.MP.0000056981.16578.C3","article-title":"Value of mesothelin immunostaining in the diagnosis of mesothelioma.","volume":"16","author":"Ordonez","year":"2003","journal-title":"Mod Pathol"},{"key":"2022061021010994300_bib6","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1309\/F1B64CL7H8VJKEAF","article-title":"Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis.","volume":"124","author":"Hassan","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"2022061021010994300_bib7","first-page":"3862","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).","volume":"7","author":"Argani","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2022061021010994300_bib8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.pai.00000141545.36485.d6","article-title":"Localization of mesothelin in epithelial ovarian cancer.","volume":"13","author":"Hassan","year":"2005","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2022061021010994300_bib9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00000478-200302000-00002","article-title":"Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura.","volume":"27","author":"Miettinen","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"2022061021010994300_bib10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.lungcan.2009.07.016","article-title":"Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.","volume":"68","author":"Hassan","year":"2010","journal-title":"Lung Cancer"},{"key":"2022061021010994300_bib11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/1535-7163.MCT-11-0454","article-title":"Mesothelin-targeted agents in clinical trials and in preclinical development.","volume":"11","author":"Kelly","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"2022061021010994300_bib12","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","article-title":"Mesothelin: a new target for immunotherapy.","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2022061021010994300_bib13","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion.","volume":"279","author":"Rump","year":"2004","journal-title":"J Biol Chem"},{"key":"2022061021010994300_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol Cancer"},{"key":"2022061021010994300_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2559.1996.d01-562.x","article-title":"Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression.","volume":"30","author":"Bateman","year":"1997","journal-title":"Histopathology"},{"key":"2022061021010994300_bib16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1078-0432.CCR-05-1477","article-title":"Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer.","volume":"12","author":"Hassan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2022061021010994300_bib17","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma.","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"key":"2022061021010994300_bib18","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1164\/rccm.200907-1020OC","article-title":"Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.","volume":"181","author":"Hollevoet","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2022061021010994300_bib19","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1158\/1078-0432.CCR-06-0472","article-title":"Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.","volume":"12","author":"Onda","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2022061021010994300_bib20","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1158\/1055-9965.EPI-05-0334","article-title":"Mesothelin variant 1 is released from tumor cells as a diagnostic marker.","volume":"15","author":"Hellstrom","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022061021010994300_bib21","first-page":"20","article-title":"Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.","volume":"7","author":"Hassan","year":"2007","journal-title":"Cancer Immun"},{"key":"2022061021010994300_bib22","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2022061021010994300_bib23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.lungcan.2009.07.016","article-title":"Inhibition of mesothelin\u2013CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: implications for cancer therapy.","volume":"68","author":"Hassan","year":"2010","journal-title":"Lung Cancer"},{"key":"2022061021010994300_bib24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"2022061021010994300_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials.","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"2022061021010994300_bib26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric-estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2022061021010994300_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence-interval for the median survival-time.","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"2022061021010994300_bib28","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2307\/2529881","article-title":"Maximally selected chi square statistics.","volume":"38","author":"Miller","year":"1982","journal-title":"Biometrics"},{"key":"2022061021010994300_bib29","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2005.07.050","article-title":"Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.","volume":"23","author":"Fennell","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022061021010994300_bib30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00001622-199104000-00014","article-title":"Pleural mesothelioma.","volume":"3","author":"Ruffie","year":"1991","journal-title":"Curr Opin Oncol"},{"key":"2022061021010994300_bib31","first-page":"660","article-title":"Prognostic factors in diffuse malignant mesothelioma of the pleura.","volume":"43","author":"Schildge","year":"1989","journal-title":"Pneumologie"},{"key":"2022061021010994300_bib32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lungcan.2008.02.012","article-title":"Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.","volume":"62","author":"Iwahori","year":"2008","journal-title":"Lung Cancer"},{"key":"2022061021010994300_bib33","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/JTO.0b013e318180477b","article-title":"Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.","volume":"3","author":"Creaney","year":"2008","journal-title":"J Thorac Oncol"},{"key":"2022061021010994300_bib34","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1200\/JCO.2009.26.9944","article-title":"Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma.","volume":"8","author":"Wheatley-Price","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/20\/23\/5927\/1924654\/5927.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/20\/23\/5927\/1924654\/5927.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T21:56:11Z","timestamp":1654898171000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/20\/23\/5927\/13824\/Phase-II-Clinical-Trial-of-Amatuximab-a-Chimeric"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,30]]},"references-count":34,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2014,11,30]]},"published-print":{"date-parts":[[2014,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-0804","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/1078-0432.c.6523112","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22455761.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.c.6523112.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22455761","asserted-by":"object"}]},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,30]]}}}